ReviewArchives of gynecology and obstetrics2025
Therapy of early breast cancer: current status and perspectives.
Review in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Accuracy of ctDNA-based minimal residual disease detection in predicting postoperative recurrence of breast cancer: a meta-analysis.Frontiers in oncology · 2026Pooled it
- Article
- Real-world insights into bone marrow carcinomatosis in metastatic breast cancer: a retrospective analysis from two large university breast cancer centers.Journal of cancer research and clinical oncology · 2026Article
- Financial distress among women with advanced or metastatic breast cancer in Germany: secondary analysis of prospective ePROCOM data of a two-center cohort.Archives of gynecology and obstetrics · 2026Article
- AI-enabled clinical decision support in breast cancer care: a blinded multicenter benchmarking study comparing medically specialized with a general-purpose system.Journal of medical systems · 2026Article
- A Theranostic Study ofBioconjugate chemistry · 2026Article
- Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.Current treatment options in oncology · 2026Review
- Surgical Decision-Making in Breast Cancer: A Retrospective Comparative Study from a Tertiary Center.Journal of clinical medicine · 2026Article
- Emerging roles for SNRPB2 in governing the cell cycle and steering tumor immune modulation in breast cancer.Molecular biology reports · 2026Article
- Severe fetomaternal transfusion due to an unrecognized chorangioma in a dichorionic, diamniotic twin pregnancy.Archives of gynecology and obstetrics · 2026Review
- Genetic tumor syndromes in female cancer: insights into inherited cancer predisposition and clinical implications.Archives of gynecology and obstetrics · 2026Review
- Circular RNAs in Plasma and Beyond: Potential Biomarkers for Breast Cancer.Oncology research · 2026Review
- Efficacy and safety of pyrotinib combined with trastuzumab and chemotherapy in patients with HER2-positive locally advanced breast cancer: a multicenter real-world study.American journal of translational research · 2026Article
- Time Toxicity of Endocrine-based Oral CDK4/6 Inhibitor Therapies.Geburtshilfe und Frauenheilkunde · 2026Article
- Quality of care before and after initial certification at a German certified hereditary breast and ovarian cancer center.Journal of cancer research and clinical oncology · 2025Article
- AXINEO: AXIllary response to NEOadjuvant chemotherapy for breast cancer: can we predict response based on a biomarker panel?Archives of gynecology and obstetrics · 2025Article
- Secondary hemophagocytic lymphohistiocytosis associated with adjuvant pembrolizumab therapy in a young patient with triple-negative breast cancer: a case report with literature review.Archives of gynecology and obstetrics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medical advancements in breast cancer are truly remarkable. Especially in recent years, numerous new therapeutics have been approved and surgical strategies have been de-escalated for specific patient groups. In the therapeutic setting, CDK4/6 inhibitors as oral maintenance therapy in early breast cancer and immune checkpoint inhibitors (Pembrolizumab) for triple-negative breast cancer (BC) are noteworthy. In the surgical field, prospective randomized controlled trials have currently explored the possibility to deescalate axillary surgery by omitting sentinel lymph node excision (INSEMA, SOUND). As a result, there have been significant improvements in prognosis and a reduction in surgical morbidity for patients. Many exciting trials are underway, and it remains to be seen whether antibody-drug conjugates beyond trastuzumab emtansine, will find their way into the treatment lines for early-stage BC. Furthermore, the integration of artificial intelligence in both diagnostics and treatment recommendation evaluation is a promising area with great potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.